Overview

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-11-16

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Necitumumab
Osimertinib
Ramucirumab